Evidence map›Paper›PMID 31958307›Full record

Observational studyBMJ open diabetes research & care2020

Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease.

Laura Mayeda, Ronit Katz, Iram Ahmad, Nisha Bansal, Zona Batacchi, Irl B Hirsch, Nicole Robinson, Dace L Trence, Leila Zelnick, Ian H de Boer

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Laura MayedaVirginia Mason Medical Center, Seattle, Washington, USA lamayeda@uw.edu.ORCID http://orcid.org/0000-0002-9255-5673
Ronit KatzKidney Research Institute and Division of Nephrology, University of Washington, Seattle, Washington, USA.
Iram AhmadDivision of Endocrinology, Banner-MD Anderson Health System, Gilbert, Arizona, USA.
Nisha BansalKidney Research Institute and Division of Nephrology, University of Washington, Seattle, Washington, USA.
Zona BatacchiDivision of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington, USA.
Irl B HirschDivision of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington, USA.
Nicole RobinsonKidney Research Institute and Division of Nephrology, University of Washington, Seattle, Washington, USA.
Dace L TrenceDivision of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington, USA.
Leila ZelnickKidney Research Institute and Division of Nephrology, University of Washington, Seattle, Washington, USA.
Ian H de BoerKidney Research Institute and Division of Nephrology, University of Washington, Seattle, Washington, USA.
University of Washington · USBanner Health · USVirginia Mason Medical Center · US

Funding

Diabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0M
Nutrition, Obesity and Atherosclerosis Training ProgramT32HL007028 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1985 to 2026
$6.4M
Randomized trial of vitamin D and omega-3 fatty acids for diabetic kidney diseaseR01DK088762 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2019
$4.7M
Insulin Resistance in Chronic Kidney DiseaseR01DK087726 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2013
$1.9M
NHLBI NIH HHS T32 HL007028NIDDK NIH HHS R01 DK087726NIDDK NIH HHS R01 DK088762NIDDK NIH HHS T32 DK007247
6 · The paper itself

Abstract

​

objectiveCompared with hemoglobin A1c (HbA1c), continuous glucose monitoring (CGM) may better capture risk of diabetes complications in patients with chronic kidney disease (CKD), including diabetic peripheral neuropathy (DPN). We hypothesized that glucose time in range (TIR), measured by CGM, is associated with DPN symptoms among participants with type 2 diabetes mellitus (type 2 DM) and moderate-to-severe CKD. ​RESEARCH DESIGN AND

methodsWe enrolled 105 people with type 2 DM treated with insulin or sulfonylurea, 81 participants with CKD (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m

Indexed as

AgedBiomarkersBlood GlucoseBlood Glucose Self-MonitoringCase-Control StudiesDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlomerular Filtration RateGlycated HemoglobinHumansMaleMiddle AgedPeripheral Nervous System DiseasesPrognosisProspective StudiesBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humandiabetesdiabetic footglucose monitoringnephropathyneuropathy

Identifiers

PMID31958307
PMCPMC7039577
OpenAlexW3000563589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.